| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $283,805 ) |
| | 2025 | 2025 | INVIZYNE TECHNOLOGIES, INC | 750 ROYAL OAKS DR STE 106 | MONROVIA | CA | 91016-6357 | LOS ANGELES | USA | R43GM157956 | Bio-Click: A cell-free high-throughput platform for the engineering of enzymatic group transfer reactions | 000 | 1 | NIH | 3/26/2025 | $283,805 |
| | 2025 | 2024 | INVIZYNE TECHNOLOGIES, INC | 750 ROYAL OAKS DR STE 106 | MONROVIA | CA | 91016-6357 | LOS ANGELES | USA | R43GM153108 | GlyCoSAM: Glycolysis coupled S-adenosyl methionine regeneration for cell-free methylation reactions | 000 | 1 | NIH | 5/6/2025 | $0 |
| | 2025 | 2023 | INVIZYNE TECHNOLOGIES, INC | 750 ROYAL OAKS DR STE 106 | MONROVIA | CA | 91016-6357 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 000 | 4 | NIH | 2/5/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $243,527 ) |
| | 2024 | 2024 | INVIZYNE TECHNOLOGIES INC | 750 ROYAL OAKS DRIVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R43GM153108 | GlyCoSAM: Glycolysis coupled S-adenosyl methionine regeneration for cell-free methylation reactions | 000 | 1 | NIH | 1/12/2024 | $243,527 |
|
| Issue Date FY: 2023 ( Subtotal = $685,848 ) |
| | 2023 | 2023 | INVIZYNE TECHNOLOGIES INC | 750 ROYAL OAKS DRIVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 000 | 3 | NIH | 7/27/2023 | $6,834 |
| | 2023 | 2023 | INVIZYNE TECHNOLOGIES INC | 750 ROYAL OAKS DRIVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 002 | 4 | NIH | 9/5/2023 | $47,840 |
| | 2023 | 2023 | INVIZYNE TECHNOLOGIES INC | 750 ROYAL OAKS DRIVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 001 | 4 | NIH | 9/1/2023 | $631,174 |
|
| Issue Date FY: 2022 ( Subtotal = $718,833 ) |
| | 2022 | 2022 | INVIZYNE TECHNOLOGIES, INC. | 140 W CHESTNUT AVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 001 | 2 | NIH | 12/10/2021 | $71,828 |
| | 2022 | 2022 | INVIZYNE TECHNOLOGIES INC | 140 W CHESTNUT AVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 002 | 3 | NIH | 9/6/2022 | $647,005 |
| | 2022 | 2021 | INVIZYNE TECHNOLOGIES, INC. | 140 W CHESTNUT AVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 000 | 2 | NIH | 11/10/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $649,993 ) |
| | 2021 | 2021 | INVIZYNE TECHNOLOGIES, INC. | 140 W CHESTNUT AVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R44AT011482 | SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis | 000 | 2 | NIH | 8/27/2021 | $649,993 |
| | 2021 | 2020 | INVIZYNE TECHNOLOGIES, INC. | 140 W CHESTNUT AVE | MONROVIA | CA | 91016-3412 | LOS ANGELES | USA | R43GM137635 | SimplePath: A Cell-free Enzymatic Platform for Cannabinoid Boisynthesis | 000 | 1 | NIH | 8/8/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $150,000 ) |
| | 2020 | 2020 | INVIZYNE TECHNOLOGIES, INC | 10866 WASHINGTON BLVD #94 | CULVER CITY | CA | 90232-3610 | LOS ANGELES | USA | R43GM137635 | SimplePath: A Cell-free Enzymatic Platform for Cannabinoid Boisynthesis | 000 | 1 | NIH | 3/27/2020 | $150,000 |
|
|
